Skip to main content

#151105

Anti-Integrin a2 [HAS-4]

Cat. #151105

Anti-Integrin a2 [HAS-4]

Cat. #: 151105

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 3-4 weeks

Target: Integrin a2 (CD49b)

Class: Monoclonal

Application: FACS ; IHC ; IF ; IP

Reactivity: Human

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Fiona Watt

Institute: Cancer Research UK, London Research Institute: Lincoln's Inn Fields

Primary Citation: Tenchini et al. 1993. Cell Adhes Commun. 1(1):55-66. PMID: 7521749.

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: Anti-Integrin a2 [HAS-4]
  • Alternate name: Integrin Subunit Alpha 2; Alpha 2 Subunit Of VLA-2 Receptor; Platelet Membrane Glycoprotein Ia; CD49 Antigen-Like Family Member B; Collagen Receptor; CD49B; GPIa; Very Late Activation Protein 2 Receptor, Alpha-2 Subunit; Human Platelet Alloantigen System 5; Platelet Glycoprotein GPIa; Platelet Antigen Br; VLA-2 Subunit Alpha; CD49b Antigen; HPA-5; VLA-2; VLAA2; BR
  • Research fields: Cancer;Cell biology;Cell signaling and signal transduction;Metabolism
  • Clone: HAS-4
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Reactivity: Human
  • Host: Mouse
  • Application: FACS ; IHC ; IF ; IP
  • Description: Integrins are heterodimeric cell surface receptors composed of alpha and beta subunits, which mediate cell-cell and cell-extracellular matrix attachments. Aberrant integrin expression has been found in many epithelial tumours. Changes in integrin expression have been shown to be important for the growth and early metastatic capacity of melanoma cells. Integrin a2 associates with integrin b1 (CD29) to form the heterodimer integrin a2b1, which is one of the most abundant keratinocyte integrins, is found distributed in the basal layer of epidermis and binds collagen. HAS-4 co-precipitates integrin a2b1 from keratinocytes and inhibits HGF-induced branching morphogenesis and motility of human mammary epithelial HB2 cells in collagen.
  • Immunogen: Whole human keratinocytes.
  • Immunogen uniprot id: P17301
  • Isotype: IgG2a
  • Myeloma used: Sp2/0-Ag14

Target Details

  • Target: Integrin a2 (CD49b)
  • Target background: Integrins are heterodimeric cell surface receptors composed of alpha and beta subunits, which mediate cell-cell and cell-extracellular matrix attachments. Aberrant integrin expression has been found in many epithelial tumours. Changes in integrin expression have been shown to be important for the growth and early metastatic capacity of melanoma cells. Integrin a2 associates with integrin b1 (CD29) to form the heterodimer integrin a2b1, which is one of the most abundant keratinocyte integrins, is found distributed in the basal layer of epidermis and binds collagen. HAS-4 co-precipitates integrin a2b1 from keratinocytes and inhibits HGF-induced branching morphogenesis and motility of human mammary epithelial HB2 cells in collagen.

Applications

  • Application: FACS ; IHC ; IF ; IP

Handling

  • Format: Liquid
  • Concentration: 1 mg/ml
  • Unit size: 100 ug
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: -15° C to -25° C
  • Shipping conditions: Dry ice

References

  • Malara et al. 2011. Blood. 117(8):2476-83. PMID: 21131589.
  • Owens et al. 2001. Cancer Res. 61(13):5248-54. PMID: 11431366.
  • Alford et al. 1998. J Cell Sci. 111 ( Pt 4):521-32. PMID: 9443900.
  • Tenchini et al. 1993. Cell Adhes Commun. 1(1):55-66. PMID: 7521749.

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.